Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-01
DOI
10.1038/s41467-019-08466-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Leptin Mediates a Glucose-Fatty Acid Cycle to Maintain Glucose Homeostasis in Starvation
- (2018) Rachel J. Perry et al. CELL
- SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications
- (2018) Emily J. Meyer et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report
- (2018) Felicity Brown et al. JOURNAL OF EMERGENCY MEDICINE
- Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
- (2018) David Fitchett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Euglycemic diabetic ketoacidosis caused by dapagliflozin
- (2018) Yu-Mou Chou et al. MEDICINE
- Euglisemic diabetic ketoacidotic coma caused by dapagliflozin
- (2018) Zeynep Karakaya et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
- (2017) Junichiro Adachi et al. INTERNAL MEDICINE
- Mechanism for leptin’s acute insulin-independent effect to reverse diabetic ketoacidosis
- (2017) Rachel J. Perry et al. JOURNAL OF CLINICAL INVESTIGATION
- Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor
- (2017) Tory J. Andrews et al. JOURNAL OF EMERGENCY MEDICINE
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
- (2017) Michael Fralick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes
- (2016) Anne L. Peters et al. DIABETES CARE
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
- (2016) Giuseppe Daniele et al. DIABETES CARE
- Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive MedicationNovelty and Significance
- (2016) Giuseppe Mancia et al. HYPERTENSION
- EMPA-REG: Glucose excretion and lipid mobilization – not storage – saves lives
- (2016) Nils Bruun Jørgensen et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice
- (2016) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients
- (2016) Aki Okamoto et al. Drugs in research & development
- Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells
- (2016) Morten Gram Pedersen et al. Scientific Reports
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes
- (2015) Rachel J. Perry et al. CELL
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
- (2015) Elza Muscelli et al. DIABETOLOGIA
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- SGLT-2 inhibition and glucagon: Cause for alarm?
- (2015) Richard G. Kibbey TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Postprandial Dynamics of Plasma Glucose, Insulin, and Glucagon in Patients with Type 2 Diabetes Treated with Saxagliptin Plus Dapagliflozin Add-On to Metformin Therapy
- (2014) Lars Hansen et al. Endocrine Practice
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
- (2014) Masanori Yokono et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis
- (2014) Rachel J Perry et al. NATURE MEDICINE
- Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
- (2014) M Suzuki et al. Nutrition & Diabetes
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
- (2011) Michael J. Jurczak et al. DIABETES
- Functional expression of SGLTs in rat brain
- (2010) Amy S. Yu et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More